Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: Subanalysis of the CASE-J Trial

Circulation Journal

Volumn 73, Issue 6, 2009, Pages 1080-1085

  Ueshima, Kenji ^a   Yasuno, Shinji ^a   Oba, Koji ^a   Fujimoto, Akira ^a   Ogihara, Toshio ^b   Saruta, Takao ^c   Nakao, Kazuwa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA GENERAL MEDICAL CENTER   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Coronary heart disease; Hypertension; Hypertrophy; Japanese

Indexed keywords

AMLODIPINE; CANDESARTAN;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTERIOSCLEROSIS; ARTERY OCCLUSION; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISSECTING ANEURYSM; DRUG EFFECT; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; JAPAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH; VASCULAR DISEASE;

ADRENERGIC ANTAGONISTS; AGED; AMLODIPINE; BENZIMIDAZOLES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; JAPAN; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PROGNOSIS; RISK FACTORS; TETRAZOLES;

EID: 67649877865     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0886     Document Type: Article

References (29)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005; 365: 217-223. (Pubitemid 40138015)
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet 2006; 367: 1747-1757.
3. Nakamura Y, Saitoh S, Takagi S, Ohnishi H, Chiba Y, Kato N, et al. Impact of abnormal glucose tolerance, hypertension, and other risk factors on coronary heart disease. Circ J 2007; 71: 20-25. (Pubitemid 46045545)
4. Kohro T, Hayashi D, Okada Y, Yamazaki T, Nagai R; JCAD Investigators. Demographics and changes in medical/interventional treatment of coronary artery disease patients over a 3.5-year period in Japan: The Japanese Coronary Artery Disease Study: Trend examination. Circ J 2008; 72: 1397-1402.
5. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289: 2560-2572.
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536.
7. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension. Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613-634.
8. Fukui T, Rahman M, Hayashi K, Takeda K, Higaki J, Sato T, et al. Candesartan Antihypertensive Survival Evaluation in JAPAN (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: Rationale, design, and methods. Hypertens Res 2003; 26: 979-990. (Pubitemid 38128771)
9. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, et al, Candesartan Antihypertensive Survival Evaluation in Japan trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension 2008; 51: 393-398.
10. Grossman W, Jones D, McLaurin P. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 1975; 56: 56-64.
11. Ganau A, Devereux RB, Pickering TG, Roman MJ, Schnall PL, Santucci S, et al. Relation of left ventricular hemodynamic load and contractile performance to left ventricular mass in hypertension. Circulation 1990; 81: 25-36. (Pubitemid 20031763)
12. Meijs MF, De Windt LJ, De Jonge N, Cramer MJ, Bots ML, Mali WP, et al. Left ventricular hypertrophy: A shift in paradigm? Curr Med Chem 2007; 14: 157-171. (Pubitemid 46043911)
13. Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure: Insights from the Framingham Study. J Cardiovasc Pharmacol 1987; 10(Suppl 6): S135-S140.
14. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566. (Pubitemid 20176696)
15. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000; 140: 848-856.
16. Heckbert SR, Post W, Pearson GD, Arnett DK, Gomes AS, Jerosch-Herold M, et al. Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systotic function by cardiac magnetic resonance imaging: The Multiethnic Study of Atherosclerosis. J Am Coll Cardiol 2006; 48: 2285-2292.
17. Krauser DG, Devereux RB. Ventricular hypertrophy and hypertension: Prognostic elements and implications for management. Herz 2006; 31: 305-316. (Pubitemid 44046493)
18. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370: 591-603. (Pubitemid 47247855)
19. de Simone G. Left ventricular geometry and hypotension in end-stage renal disease: A mechanical perspective. J Am Soc Nephrol 2003; 14: 2421-2427. (Pubitemid 37169327)
20. Shigematsu Y, Hamada M, Ohtsuka T, Hashida H, Ikeda S, Kuwahara T, et al. Left ventricular geometry as an independent predictor for extracardiac target organ damage in essential hypertension. Am J Hypertens 1998 11: 1171-1177. (Pubitemid 28494179)
21. Fox ER, Alnabhan N, Penman AD, Butler KR, Taylor HA Jr, Skelton TN, et al. Echocardiographic left ventricular mass index predicts incident stroke in African Americans: Atherosclerosis Risk in Communities (ARIC) Study. Stroke 2007; 38: 2686-2691. (Pubitemid 47500093)
22. Ravipati G, Aronow WS, Ann C, Alappat RM, McClung JA, Weiss MB. Incidence of new stroke or new myocardial infarction or death at 39-month follow-up in patients with diabetes mellitus, hypertension or both with and without rnicroalbuminuria. Cardiology 2008; 109: 62-65. (Pubitemid 350242706)
23. Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens 2005; 23(Suppl 1): S27-S33. (Pubitemid 40646461)
24. Thune JJ, Signoroviteh J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, et al. Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. Hypertension 2008; 51: 48-54. (Pubitemid 350307103)
25. Kramer H, Jacobs DR Jr, Bild D, Post W, Saad MF, Detrano R, et al. Urine albumin excretion and subclinical cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis. Hypertension 2005; 46: 38-43. (Pubitemid 40946488)
26. Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlöf B, et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study (Losartan Intervention for Endpoint Reduction). Am Heart J 2002; 143: 319-326.
27. Lieb W, Mayer B, Stritzke J, Doering A, Hense HW, Loewel H, et al. Association of low-grade urinary albumin excretion with left ventricular hypertrophy in the general population: The MONICA/KORA Augsburg Echocardiographic Substudy. Nephrol Dial Transplant 2006; 21: 2780-2787.
28. Salles GF, Fiszman R, Cardoso CR, Muxfeldt ES. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension 2007; 50: 723-728. (Pubitemid 47442737)
29. Ueshima K, Oba K, Yasuno S, Fujimoto A, Sato Y, Fukiyama K, et al. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: Rationale, design, and characteristics of Candesartan Antihypertensive Survival Evaluation in Japan Extension (CASE-J Ex). Contemp Clin Trials 2009; 30: 97-101.